Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Cipher Pharmaceuticals Reports Fourth Quarter

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Mar 14, 2024 5:55pm

196 Views

Post# 35933727

Cipher Pharmaceuticals Reports Fourth Quarter

(All figures are presented in U.S. Dollars)

Cash at December 31, 2023 was $39.8 million (CDN$52.7 million) or $1.66 per outstanding common share (CDN$2.20)
Full year adjusted EBITDA of $12.7 million, an increase of 2.2% over fiscal 2022
Epuris revenue grew by 10% in Q4 2023 compared to Q4 2022
Licensing revenue increased 4.1% to $8.5 million in 2023
Product revenue increased 1.2% to $12.7 million in 2023

MISSISSAUGA, ON, March 14, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the year ended December 31, 2023.

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results (newswire.ca)